Search research articles
Contact Us
Filters
Showing results (121-130 of 133) with videos related to
Page
of 14
Sort By:
JAMA Neurology
|
November 6, 2023
Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial
Daniel Lee, Mary Slomkowski, Nanco Hefting, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists
|
December 1, 2016
Ideomotor limb apraxia as a staging tool in individuals with Alzheimer's disease (ILIAD)
William D Soulsby, Nezar El-Ruwie, Shravan Gatla, et al.
Current Medical Research and Opinion
|
August 23, 2025
Brexpiprazole for agitation in clinically relevant patient subgroups: a <i>post hoc</i> analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer's disease
Jared Stroud, Jeffrey L Cummings, Sanjeda R Chumki, et al.
Journal of Clinical Psychopharmacology
|
January 18, 2006
An open-label trial of adjunctive oxcarbazepine for bipolar disorder
Charles R Conway, John T Chibnall, Leigh Anne Nelson, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
November 12, 2019
Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials
George T Grossberg, Eva Kohegyi, Victor Mergel, et al.
Brain : a Journal of Neurology
|
June 1, 2018
The cholinergic system in the pathophysiology and treatment of Alzheimer's disease
Harald Hampel, M-Marsel Mesulam, A Claudio Cuello, et al.
CNS Drugs
|
July 18, 2025
Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial
Alpesh Shah, Alvin Estilo, Pamela L Sheridan, et al.
CNS Drugs
|
June 5, 2013
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors
George T Grossberg, Facundo Manes, Ricardo F Allegri, et al.
The Journal of Clinical Psychiatry
|
May 23, 2008
Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy
Carl Salzman, Dilip V Jeste, Roger E Meyer, et al.
Journal of the American Medical Directors Association
|
April 8, 2014
International survey of nursing home research priorities
John E Morley, Gideon Caplan, Matteo Cesari, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 133) with videos related to
Sort By:
Page
of 14
JAMA Neurology
|
November 6, 2023
Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial
Daniel Lee, Mary Slomkowski, Nanco Hefting, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists
|
December 1, 2016
Ideomotor limb apraxia as a staging tool in individuals with Alzheimer's disease (ILIAD)
William D Soulsby, Nezar El-Ruwie, Shravan Gatla, et al.
Current Medical Research and Opinion
|
August 23, 2025
Brexpiprazole for agitation in clinically relevant patient subgroups: a <i>post hoc</i> analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer's disease
Jared Stroud, Jeffrey L Cummings, Sanjeda R Chumki, et al.
Journal of Clinical Psychopharmacology
|
January 18, 2006
An open-label trial of adjunctive oxcarbazepine for bipolar disorder
Charles R Conway, John T Chibnall, Leigh Anne Nelson, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
November 12, 2019
Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials
George T Grossberg, Eva Kohegyi, Victor Mergel, et al.
Brain : a Journal of Neurology
|
June 1, 2018
The cholinergic system in the pathophysiology and treatment of Alzheimer's disease
Harald Hampel, M-Marsel Mesulam, A Claudio Cuello, et al.
CNS Drugs
|
July 18, 2025
Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial
Alpesh Shah, Alvin Estilo, Pamela L Sheridan, et al.
CNS Drugs
|
June 5, 2013
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors
George T Grossberg, Facundo Manes, Ricardo F Allegri, et al.
The Journal of Clinical Psychiatry
|
May 23, 2008
Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy
Carl Salzman, Dilip V Jeste, Roger E Meyer, et al.
Journal of the American Medical Directors Association
|
April 8, 2014
International survey of nursing home research priorities
John E Morley, Gideon Caplan, Matteo Cesari, et al.
Page
of 14